Gilead Seeks First-Ever HIV Prevention Indication for Blockbuster Truvada

Drug Industry Daily
A A
Gilead Sciences filed an sNDA for its antiretroviral Truvada, seeking an indication as the first drug to reduce the risk of sexually transmitted HIV.

To View This Article:

Login

Subscribe To Drug Industry Daily